Navigation Links
Significant Reduction in Pain With the Mynx Vascular Closure Device Versus Angio-Seal Device
Date:3/8/2011

MOUNTAIN VIEW, Calif., March 9, 2011 /PRNewswire/ -- AccessClosure, Inc., the U.S. market segment leader in extravascular closure devices, announced today results from the first published study* (Journal of NeuroInterventional Surgery) comparing the pain associated with deployment of different vascular closure devices (VCD) as the primary endpoint.  The single-blinded, randomized, single-center, controlled trial compared the discomfort associated with the Mynx 5F Vascular Closure Device versus the Angio-Seal Evolution Device.  Both pain at closure and the pain increase from baseline to closure were significantly higher in patients undergoing closure with the Angio-Seal Evolution device (p=0.009 and 0.002, respectively).  There was no difference in the rate of closure success or closure complications between the devices.

"This is an important study for physicians and patients,'' said Gregory D. Casciaro, President and CEO of AccessClosure.  "The study scientifically examined whether the Mynx device reduced the pain associated with arteriotomy closure seen with the Angio-Seal Evolution device and provides an evidence-based understanding that will help guide choice about VCD options."

The Institutional Review Board-approved study provided for enrollment of 128 patients based on power analyses with the intention of performing preliminary statistical analysis following enrollment of 64 patients (32 patients in each arm).  Patients, nurses administering a commonly utilized, well-validated visual analog scale (VAS) to assess patient pain, and study coordinators were blinded to the VCD treatment.  The primary end point was defined as the change in pain from baseline (pre-closure) to post-closure, assessed by the VAS.  The patient's reporting of the most painful part of the procedure from a multiple choice selection (1. Lidocaine injection and access, 2. contrast injection and 3. closure) was a secondary endpoint along with
'/>"/>

SOURCE AccessClosure, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Georgia Health Sciences University Clinical Study Shows RyMed InVision-Plus® IV Connector Significantly Decreased Central Venous Catheter Occlusions in Oncology Patients
2. Leading Animal Stem Cell Developer MediVet-America Achieves Significant Business Growth Milestones in First Year
3. The New England Journal of Medicine Publishes Results of Fidaxomicin Phase 3 Trial Showing Significantly Lower Recurrence Rates and Improved Global Cure Rates Compared to Vancomycin in Patients with Clostridium difficile Infection (CDI)
4. Structured Diabetes Management can Significantly Improve Overall Glycemic Control and Reduce HbA1c Values in Non-insulin Treated Type 2 Diabetes
5. Integrated Analysis Demonstrates Alpha(1)-Augmentation Therapy Significantly Reduces Loss of Lung Tissue in Patients with AAT-deficiency-related Emphysema
6. US Dominance in Scientific Research Significantly Challenged by Increased Competition from Europe and Asia, According to Thomson Reuters Study
7. YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS
8. STALLERGENES : Significant Growth : Q3 2010 + 10% and +12% Over the First 9 Months / Shionogi Partnership: First EUR24 Million Instalment
9. Spherix Announces Statistically Significant Results in Phase 3 Study With D-tagatose in Type 2 Diabetes
10. Cord Blood America Says Outreach Program to OB/GYN Nurses, Insurance Case Workers, Paying Significant Dividends
11. Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... City, CA (PRWEB) , ... August 31, 2015 , ... ... System. Minerva is the first commercially available new FDA approved system in ... treatment Success rate of 92%, the high Amenorrhea (zero bleeding) rate of 66%, the ...
(Date:8/31/2015)... ... ... Proove Biosciences, Inc. is a finalist for the Outstanding Tech Company category of ... its 22nd year, this premier awards event celebrates the best in Orange County’s technology ... world. The OC Tech Alliance will announce all winners at a gala dinner on ...
(Date:8/30/2015)... , England , August 31, ... beendet die 51-jährige Wartezeit   einer Frau   für ... Frauen im Alter von 7-90   werden ... Programm soll 1200 Frauen behandeln und die ... , Astellas gab heute bekannt, ...
(Date:8/28/2015)... Research and Markets ( http://www.researchandmarkets.com/research/zsgg5n/global_and_usa ) ... USA BioSimilar Market Analysis to 2021" report to ... market will be initiated in September as Sandoz launches ... global market react? Will biosimilars explode into the biologics ... US economy up to $250 billion within the next ...
Breaking Biology Technology:U.S. FDA Approves Minerva Endometrial Ablation System 2U.S. FDA Approves Minerva Endometrial Ablation System 3Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 2Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 3Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 4Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 2Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 3Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 4Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 5Global & USA BioSimilar Market Analysis Report 2015-2021 2Global & USA BioSimilar Market Analysis Report 2015-2021 3
... law firm of Finkelstein,Thompson LLP announces that a class ... Court for the Southern District of New York on,behalf ... GPC Biotech AG,("GPC Biotech" or the "Company") (Nasdaq: ... inclusive (the "Class Period"). Finkelstein Thompson LLP,is investigating similar ...
... BioSciences Inc.,(AMEX: YMI , TSX: YM, AIM: ... differentiated products for patients worldwide,today announced that Oncoscience ... of the humanized EGFR-targeting monoclonal antibody,nimotuzumab, has advised ... commence in Europe. - A ...
... -- Sinovac Biotech Ltd. (Amex:,SVA), a leading ... shareholders today that the Annual General Meeting ... been postponed due the geographical,nature of its ... of,proxy materials. The Company is currently working ...
Cached Biology Technology:Finkelstein Thompson LLP Announces GPC Biotech AG Investigation 2YM BIOSCIENCES', EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER 2YM BIOSCIENCES', EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER 3YM BIOSCIENCES', EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER 4Sinovac Announces Postponement of Annual General Meeting 2
(Date:8/6/2015)... JOSE, Calif. , Aug. 6, 2015 /PRNewswire/ ... leading developer of human interface solutions, today announced ... TouchPad technologies on Windows 10. Microsoft leveraged Synaptics, ... to the operating system. Through ... drivers are fully certified with Microsoft,s Precision TouchPad ...
(Date:8/4/2015)... 2015 Research ... the addition of the "Digital Forensics ... Sub-Segment (Computer Forensics, Network Forensics, Mobile Device ... Vertical and Region - Global Forecast to ... By Component (Hardware, Software, and Service), ...
(Date:7/31/2015)... de 2015 BGI llevará a cabo la 10ª ... al 25 de octubre de 2015, en ... su décimo aniversario este año. Desde su inauguración en ... reuniones anuales más influyentes del mundo en los campos ... científicas más dinámicas, entusiastas y amenas. ICG-10 ...
Breaking Biology News(10 mins):Synaptics Chosen for Human Interface Co-Development on Windows 10 2Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3
... NEW YORK, July 6, 2011 Reportlinker.com announces ... in its catalogue: Biobanking: Technologies ... REPORT HIGHLIGHTS ... * An overview of biobanks by types: Population, ...
... become as common as the stethoscope in patient,s rooms. Physicians ... access diagnostic tools and take patient notes, all with a ... a flash drive. These mobile devices are ideal for information ... to patient information. In less than two years, ...
... Accelerator announced today that it has received an investment ... the Silicon Valley. Mr Draper, who is the Founder ... is well known for making early-stage investments in dynamic ... is a technology incubator that focuses on commercialising key ...
Cached Biology News:Biobanking: Technologies and Global Markets 2Biobanking: Technologies and Global Markets 3Biobanking: Technologies and Global Markets 4Biobanking: Technologies and Global Markets 5Biobanking: Technologies and Global Markets 6Biobanking: Technologies and Global Markets 7Biobanking: Technologies and Global Markets 8Biobanking: Technologies and Global Markets 9Biobanking: Technologies and Global Markets 10Biobanking: Technologies and Global Markets 11Biobanking: Technologies and Global Markets 12Biobanking: Technologies and Global Markets 13Mobile Devices Pose New Security Risks for Patients; Five Experts Share Insights on mHealth 2Mobile Devices Pose New Security Risks for Patients; Five Experts Share Insights on mHealth 3Mobile Devices Pose New Security Risks for Patients; Five Experts Share Insights on mHealth 4Mobile Devices Pose New Security Risks for Patients; Five Experts Share Insights on mHealth 5Singapore Technology Incubator Receives Investment from Silicon Valley "Super-Angel" 2Singapore Technology Incubator Receives Investment from Silicon Valley "Super-Angel" 3Singapore Technology Incubator Receives Investment from Silicon Valley "Super-Angel" 4Singapore Technology Incubator Receives Investment from Silicon Valley "Super-Angel" 5Singapore Technology Incubator Receives Investment from Silicon Valley "Super-Angel" 6
Request Info...
... Xcell microbial system, 100 to 240 ... electroporation of bacterial and fungal cells. ... PC module for exponential decay delivery, ... (5 each of 0.1 and 0.2 ...
... Species Tissue Array (MSTA) slides were designed to ... tissues from multiple species. Tissue slices from ... slide which can then be treated as a ... in situ hybridization. This format ...
... used to predict the melting ... up to 3,200 bases, which ... primers and GC clamps for ... gel electrophoresis (DGGE), constant denaturing ...
Biology Products: